[go: up one dir, main page]
More Web Proxy on the site http://driver.im/ Skip to main content

Advertisement

Springer Nature Link
Log in

Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Summary

The interface between the tumor and the host is often the site of leucocytic infiltration. We will examine the dea that the infiltrating leucocytes of human and experimental tumors are components of the host ammunological defense against the tumor, and that the presence of the infiltrate is a marker of favorable prognosis. Leucocytes could infiltrate tumors because of an active immune response, either nonspecific or specifically directed to tumor-associated antigens. Leucocyte influx may also occur because of chemotactic factors secreted by the tumor cells. Some tumors release factors which enhance vascular permeability and permit improved access by leucocytes to the tumor focus. The consequences of leucocytic infiltration include tumor cell cytolysis, cytostasis, or stimulation of proliferation. The present state of our knowledge of the interactions between tumor cells and infiltrating leucocytes precludes broad generalization of mechanisms. Further study will probably reveal that the mechanisms are diverse, and that there are some systems in which immune interactions occur at this interface and others in which they do not.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
£29.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ehrlich P: Euber-die Specifischen Granulations des Blut. Arch Anat Physiol 3: 571–579, 1879.

    Google Scholar 

  2. Haskill S (ed): Tumor immunity in prognosis. The role of mononuclear cell infiltration. Marcel Dekker, Inc., New York, 1982.

    Google Scholar 

  3. Witz IP, Hanna MG (eds): Contemporary topics in immunobiology, Vol 10. In situ expression of tumor immunity. Plenum Publishing, New York, 1980.

    Google Scholar 

  4. Hayry P: Inflammatory response in allograft rejection. Transp Proc XV: 1897–1899, 1983.

    Google Scholar 

  5. Hancock WW, Thomson NM, Atkins RC: Monoclonal antibody analysis of interstitial cell infiltrate during human renal allograft rejection. Transp Proc XV: 352–355, 1983.

    Google Scholar 

  6. Hammer C, Land W, Stadler J, Koller C, Brendel W: Lymphocyte subclasses in rejecting kidney grafts detected by monoclonal antibodies. Transp Proc XV: 356–360, 1983.

    Google Scholar 

  7. Tufveson G, Forsum U, Claesson K, Klareskog L, Larsson E, Karlsson-Parra A, Frodin L: T-lymphocyte subsets and HLA-DR-expressing cells in rejected human kidney grafts. Scand J Immun 18: 37–40, 1983.

    Google Scholar 

  8. Friedell GH, Betts A, Sommers SC: The prognostic value of blood vessel invasion and lymphocytic infiltrates in breast carcinoma. Cancer 18: 164–166, 1965.

    Google Scholar 

  9. Bill AH: Immune aspects of neuroblastoma. Amer J Surg 122: 142–147, 1971.

    Google Scholar 

  10. Martin RF, Beckwith B: Lymphoid infiltrates in neuroblastomas their occurrence and prognostic significance. J Ped Surg 3: 161–164, 1968.

    Google Scholar 

  11. Lauder I, Aherne W: The significance of lymphocytic infiltration in neuroblastoma. Brit J Cancer 23: 321–330, 1972.

    Google Scholar 

  12. Gerson JM, Herberman RB: Systemic and in situ natural killer activity in patients with neuroblastoma. In: Evans AE (ed) Progress in cancer research and therapy Vol 12. Advances in Neuroblastoma Research. Raven Press, New York, 1980, pp 251–259.

    Google Scholar 

  13. Jacobs JB, Edelstein LM, Snyder LM, Fortier N: Ultrastructural evidence for destruction in the halo naevus. Cancer Res 35: 352–357, 1975.

    Google Scholar 

  14. Mihm MC, Clark WH, From L: The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanoma. N Eng J Med 284: 1078–1082, 1971.

    Google Scholar 

  15. Cochran AJ: Histology and prognosis in malignant melanoma. J Path 97: 459–468, 1969.

    Google Scholar 

  16. Smith JL, Stehlin JS: Spontaneous regression of primary malignant melanomas with regional metastases. Cancer 18: 1399–1415, 1965.

    Google Scholar 

  17. Weidner F, Hornstein OP: Untersuchunger zur prognostischen Bedeutung der, ‘Stromareaktion’ beim malignen melanom. II. Entzundliches infiltrat and prognose. Virchow's Arch Abt A Path Anat 359: 77–85, 1973.

    Google Scholar 

  18. Shirakawa S, Luce JK, Tannock I, Frei E: Cell proliferation in human melanoma. J Clin Invest 49: 1188–1199, 1970.

    Google Scholar 

  19. Roubin R, Cesarini JP, Fridman WH, Pavie-Fischer J, Peter HH: Characterization of the mononuclear infiltrate in human malignant melanoma. Int J Ca 16: 61–75, 1975.

    Google Scholar 

  20. Kornstein MJ, Brooks JSJ, Elder DE: Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi. Cancer Res 43: 2749–2753, 1983.

    Google Scholar 

  21. Poppema S, Brocker EB, DeLeij L, Terbrack D, Visscher T, Ter Haar A, Macher E, The TH, Sorg C: In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin. Clin Exp Immunol 51: 77–82, 1983.

    Google Scholar 

  22. Payan HM, Gilbert EF, Jacobs WH: Lymphocytic reaction around primary and metastatic melanomas. South Med J 63: 1350–1352, 1970.

    Google Scholar 

  23. Sarma KP: The role of lymphoid reaction in bladder cancer. J Urol 104: 843–849, 1970.

    Google Scholar 

  24. Tanaka T, Cooper EH, Anderson CK: Lymphocyte infiltration in bladder carcinoma. Rev Europ Etudes Clin et Biol 15: 1084–1089, 1970.

    Google Scholar 

  25. Leigh RA, van Blerk PJP, Horn BKP: Lymphocytic infiltration in bladder cancer. South African Med J 47: 192–194, 1973.

    Google Scholar 

  26. Moore OS, Foote FW: The relatively favorable prognosis of medullary carcinoma of the breast. Cancer 2: 635–642, 1949.

    Google Scholar 

  27. Black MM, Asire AJ: Palpable axillary lymph nodes in cancer of the breast. Structural and biologic consideration. Cancer 23: 251–259, 1969.

    Google Scholar 

  28. Flores L, Arlen M, Elguezabal A, Livingston SF, Levowitiz BS: Host tumor relationships in medullary carcinoma of the breast. Surg Gyn Obst 139: 683–688, 1974.

    Google Scholar 

  29. Bhan AK, DesMarais CL: Immunohistologic characterization of major histocompatibility antigen and inflammatory cellular infiltrate in human breast cancer. J Natl Cancer Inst 71: 507–516, 1983.

    Google Scholar 

  30. Sauer HR, Burke EM: Prognosis of testicular tumors. J Urol 63: 69–74, 1949.

    Google Scholar 

  31. Martin LS, Woodruff MW, Webster JH, Pukren JW: Testicular seminoma, a review of 7779 patients treated over a 50 year period. Arch Surg 90: 306–312, 1965.

    Google Scholar 

  32. Dayan A: The pathology of testicular tumors. Hosp Med 1: 126–196, 1966.

    Google Scholar 

  33. Sharma KC, Gaeta JK, Bross LD, Moore MS, Murphy GP: Testicular tumors. Histologic and epidemiologic assessment. NY State J Med 72: 2421–2425, 1972.

    Google Scholar 

  34. Johnson DE, Gomez JJ, Ayala AG: Histologic factors affecting prognosis of pure seminoma of the testis. Southern Med J 69: 1173–1174, 1976.

    Google Scholar 

  35. Schmidt JA, Mizel SB, Cohen D, Green I: Interleukin 1, a potential regulator of fibroblast proliferation. J Immunol 128: 2177–2182, 1982.

    Google Scholar 

  36. Totterman TH, Parthenais E, Hayry P: Cytological and functional analysis of inflammatory infiltrates in human malignant tumors. III. Further functional investigations using cultured autochthonous tumor cell lines and freezethawed infiltrating inflammatory cells. Cell Immunol 54: 219–226, 1980.

    Google Scholar 

  37. Akaza H, Kobayashi K, Umeda T, Niijima T: Surface markers of lymphocytes infiltrating seminoma tissue. J Urol 124: 827–828, 1980.

    Google Scholar 

  38. Ioachim HL, Dorsett BH, Paluch E: The immune response at the tumor site in lung carcinoma. Cancer 38: 2296–2309, 1976.

    Google Scholar 

  39. Lever WF, Schaumburg-Lever G: Histopathology of the skin, Sixth edition, JB Lippincott Co., Philadelphia, PA, 1983, p 483.

    Google Scholar 

  40. Alexander P, Eccles SA: The contribution of immunological factors to the control of metastatic spread of sarcomata in rats. In Miami Winter Symposium 10: 159–177, 1975.

    Google Scholar 

  41. Pross HF, Kerbel RS: An assessment of intratumor phagocytic and surface marker-bearing cells in a series of autochtonous and early passage and chemically induced murine sarcomas. J Natl Cancer Inst 57: 1157–1166, 1976.

    Google Scholar 

  42. Russell SW, Cochrane CG: The cellular events associated with regression and progression of murine (Moloney) sarcomas. Int J Cancer 13: 54–63, 1974.

    Google Scholar 

  43. Russell SW, Doe WF, Cochrane CG: Number of macrophages and distribution of mitotic activity in regressing and progressing Moloney sarcomas. J Immunol 116: 164–166, 1976.

    Google Scholar 

  44. Russell SW, Doe WF, Hoskins RG, Cochrane CG: Inflammatory cells in solid murine neoplasms. I. Tumor disaggregation and identification of constituent inflammatory cells. Int J Cancer 18: 322–330, 1976.

    Google Scholar 

  45. Russell SW, Gillespie GY, Hansen CB, Cochrane CG: Inflammatory cells in solid murine neoplasms. II. Cell types found throughout the course of Moloney sarcoma regression or progression. Int J Cancer 18: 331–338, 1976.

    Google Scholar 

  46. Holden HT, Haskill JS, Kirchner H, Herberman RB: Two functionally distinct anti-tumor effector cells isolated from primary murine sarcoma virus-induced tumors. J Immunol 117: 440–446, 1976.

    Google Scholar 

  47. Stanton MF, Law LW, Ting RC: Some biologic, immunogenic, and morphologic effects in mice after infection with a murine sarcoma virus. II. Morphologic studies. J Natl Cancer Inst 40: 1113–1129, 1968.

    Google Scholar 

  48. Haskill JS, Yamamura Y, Radov L: Host responses within solid tumors: Non thymus-derived specific cytotoxic cells within a murine mammary adenocarcinoma. Int J Cancer 16: 798–809, 1975.

    Google Scholar 

  49. Perelson AS, Bell GI: Delivery of lethal hits by cytotoxic T lymphocytes in multicellular conjugates occurs sequentially but at random times. J Immunol 129: 2796–2801, 1982.

    Google Scholar 

  50. Ioachim HL: The stromal reaction of tumors: An expression of immune surveillance. J Natl Cancer Inst 57: 465–475, 1976.

    Google Scholar 

  51. Kidd JG: The course of virus-induced rabbit papilloma as determined by virus, cells, and host. J Exp Med 67: 551–574, 1938.

    Google Scholar 

  52. Kreider JW: Neoplastic progression of the Shope rabbit papilloma. In Viruses in Naturally Occurring Cancers, Cold Spring Harbor Conferences on Cell Proliferation. 7: 283–299, 1980.

  53. Porter KA, Joseph BS, Randall JM, Stolinski C, Hoehn RJ, Calne RY: The role of lymphocytes in the rejection of canine renal transplants. Lab Invest 13: 1080–1098, 1964.

    Google Scholar 

  54. Lowry RP, Gurley KE, Blackburn J, Forbes RDC: Delayed-type hypersensitivity and lymphocytotoxicity in cardiac allograft rejection. Transpl Proc XV: 343–346, 1983.

    Google Scholar 

  55. Gurley KE, Lowry RP: Role of delayed-type hypersensitivity (DTH) in renal allograft rejection. Transpl Proc XV: 339–342, 1983.

    Google Scholar 

  56. Loveland BE, Hogarth PM, Ceredig PM, McKenzie IFC: Cells mediating graft rejection in mice. J Exptl Med 153: 1044–1057, 1981.

    Google Scholar 

  57. Alexander P, Parr IB, Jackson LE: Mechanism of the local antitumor action of inflammation. Transpl Proc XIII: 1929–1931, 1981.

    Google Scholar 

  58. Moy J, Rosenau W: Demonstration of alpha-lymphotoxin in human rejected renal allografts. Clin Immunol Immunopath 20: 49–56, 1981.

    Google Scholar 

  59. Coelho AM, Boye DB, Thomas M: Interferon and cell division. III. Effect of interferon on the division cycle of 11210 cells in vitro. J Cell Biol 48: 415–419, 1971.

    Google Scholar 

  60. Badger AM, Cooperband SR, Green JA: Direct observations on the effect of ‘proliferation inhibitory factor’ on the clonal growth of target cells. J Immunol 107: 1259–1267, 1971.

    Google Scholar 

  61. Namba Y, Jegasothy BV, Waksman BH: Regulatory substances produced by lymphocytes. V. Production of inhibitor of DNA synthesis (IDS) by proliferating T lymphocytes. J Immunol 118: 1379–1384, 1977.

    Google Scholar 

  62. Colvin RB, Johnson RA, Mihm MC, Dvorak HF: Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exptl Med 138: 686–698, 1973.

    Google Scholar 

  63. Bhan AK, Mihm MC, Dvorak HF: T cell subsets in allograft rejection. In situ characterization of T cell subsets in human skin allografts by the use of monoclonal antibodies. J Immunol 129: 1578–1583, 1982.

    Google Scholar 

  64. Deodhar SD, Benjamin SP: Pathology of human renal allograft rejection. Surg Clin N Amer 51: 1141–1159, 1971.

    Google Scholar 

  65. Dvorak HF, Dvorak AM, Manseau EJ, Wilberg L, Churchill WH: Fibrin gel investment associated with Line 1 and Line 10 solid tumor growth, angiogenesis and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in Line 1 tumor regression. J Natl Cancer Inst 62: 1459–1472, 1979.

    Google Scholar 

  66. Freemont AJ: The small blood vessels in areas of lymphocytic infiltration around malignant neoplasms. Br J Cancer 46: 283–288, 1982.

    Google Scholar 

  67. Burger DR, Vetto RM: Vascular endothelium as a major participant in T-lymphocyte immunity. Cell Immunol 70: 357–361, 1982.

    Google Scholar 

  68. Tannock IF: The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumor. Brit J Cancer 22: 258–273, 1968.

    Google Scholar 

  69. Carrel A: Growth-promoting function of leucocytes. J Exp Med 36: 385–391, 1922.

    Google Scholar 

  70. Revesz L: Effect of lethally damaged tumor cells uppon the development of admixed viable cells. J Natl Cancer Inst 20: 1157–1186, 1958.

    Google Scholar 

  71. Lambert Pb, Frank HA: Epithelial DNA synthesis within skin grafts undergoing rejection. Transp 4: 159–167, 1966.

    Google Scholar 

  72. Prehn RT: Immunostimulation of the lymphodependent phase of neoplastic growth. J Natl Cancer Inst 59: 1043–1049, 1977.

    Google Scholar 

  73. Lappe M, Schalk J: Necessity of the spleen for balanced secondary sex ratios following maternal immunization with male antigen. Transp 11: 491–495, 1971.

    Google Scholar 

  74. James DA: Effects of antigenic dissimilarity between mother and fetus on placental size in mice. Nature 205: 613–614, 1965.

    Google Scholar 

  75. Prehn RT: Influence of X-irradiation and the milk agent on growth of transplanted mouse mammary tumors. J Natl Cancer Inst 43: 1215–1220, 1969.

    Google Scholar 

  76. Heppner GH, Wood PC, Weiss DW: Studies on the role of the thymus in mammary tumor virus-induced noduligenesis and tumorigenesis. Israel Med J 4: 1195–1209, 1968.

    Google Scholar 

  77. Lappe MA, Blair PB: Interference with mammary tumorigenesis by antilymphocyte serum. Proc Amer Assoc Cancer Res 11: 47, 1970.

    Google Scholar 

  78. Prehn RT: The immune reaction as a stimulator of tumor growth. Science 176: 170–171, 1972.

    Google Scholar 

  79. Fidler IJ: In vitro studies of cellular mediated immunostimulation of tumor growth. J Natl Cancer Inst 50: 1307, 1973.

    Google Scholar 

  80. Van Wauwe JP, De Mey JR, Goossens JG: OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties. J Immunol 124: 2708–2713, 1980.

    Google Scholar 

  81. Steel GG: Growth Kinetics of Tumors. Clarendon Press, Oxford, 1977, pp 283–288.

    Google Scholar 

  82. Shearer WT, Philpott Gw, Parker CW: Stimulation of cells by antibody, Science 182: 1357–1359, 1973.

    Google Scholar 

  83. Bose BM, Moore M: Suppressor cell activity of lymphocytes infiltrating human lung and breast tumors. Int J Cancer 24: 579–585, 1979.

    Google Scholar 

  84. Haskill S, Koren H, Becker S, Fowler W, Walton L: Mononuclear cell infiltration in ovarian cancer. III. Suppressor-cell and ADCC activity of macrophages from ascitic and solid ovarian tumors. Br J Cancer 45: 747–753, 1982.

    Google Scholar 

  85. Klein E, Vanky F, Galili U, Vose BM, Fopp M: Separation and characteristics of tumor-infiltrating lymphocytes in man. In: Witz IP, Hanna MG (eds) Contemporary Topics in Immunolbiology, Vol 10. In situ expression of tumor immunity. Plenum Publishing, New York, 1980, pp 79–107.

    Google Scholar 

  86. Haskill S, Koren H, Becker S, Fowler W, Walton L: Mononuclear cell infiltration in ovarian cancer. II. Immune function of tumour and ascites-derived inflammatory cells. Br J Cancer 45: 737–746, 1982.

    Google Scholar 

  87. Vose BM: Quantitation of proliferative and cytotxic precursor cells directed against human tumours: limiting dilution analysis in peripheral blood and at the tumor site. Int J Cancer 30: 135–142, 1982.

    Google Scholar 

  88. Mantovani A, Allavena P, Sessa C, Bolis G, Mangioni C: Natural killer activity of lymphoid cells isolated from ascitic ovarian tumors. Int J Cancer 25: 573–582, 1980.

    Google Scholar 

  89. Werkmeister JA, Pihl E, Nind AP, Flannery GR, Nairn RC: Immunoreactivity by intrinsic lymphoid cells in colorectal carcinoma. Br J Cancer 40: 839–847, 1979.

    Google Scholar 

  90. Postlethwaite AE, Snyderman R: Characterization of chemotactic activity produced in vivo by a cell-mediated immune reaction in the guinea pig. J Immunol 114: 274–278, 1975.

    Google Scholar 

  91. Bottazzi B, Polentarutti N, Acero R, Balsari A, Boraschi D, Ghezzi P, Salmona M, Mantovani A: Regulation of the macrophage content of neoplasms by chemoattractants. Science 220: 210–212, 1983.

    Google Scholar 

  92. Nielsen H, Bennedsen J, Larsen SO, Dombernowsky P, Viskum K: A quantitative and qualitative study of blood monocytes in patients with bronchogenic carcinoma. Cancer Immunol Immunother 13: 93–97, 1982.

    Google Scholar 

  93. Mahoney MJ, Leighton J: The inflammatory response to a foreign body within transplantable tumors. Cancer Res 22: 334–341, 1962.

    Google Scholar 

  94. Normann SJ, Schardt M: A cancer related macrophage dysfunction in inflammed tissues. J Reticul Soc 24: 147–159, 1978.

    Google Scholar 

  95. Pretlow TP, Keith EF, Cryar AK, Bartolucci AA, Pitts AM, Pretlow TG, Kimball PM, Boohaker EA: Eosinophil infiltration of human colonic carcinomass as a prognostic indicator. Cancer Res 43: 2997–3000, 1983.

    Google Scholar 

  96. Slungaard A, Ascensao J, Zanjani E, Jacob HS: Pulmonary carcinoma with eosinophilia. Demonstration of a tumor-derived eosinophilopoietic factor. N Eng J Med 309: 778–781, 1983.

    Google Scholar 

  97. Wasserman SI: Goetzl EJ, Ellman L, Austen KF: Tumor-associated Eosinophilotactic factor. N Eng J Med 290: 420–424, 1974.

    Google Scholar 

  98. Guillino PM: Angiogenesis and oncogenesis. J Natl Cancer Inst 61: 639–643, 1978.

    Google Scholar 

  99. Goldacre RJ, Sylven B: On the access of blood-borne dyes to various tumor regions. Br J Cancer 16: 306–322, 1962.

    Google Scholar 

  100. Jungi TW, McGregor DD: Activated lymphocytes trigger lymphoblast extravasation. Cell Immunol 38: 76–83, 1978.

    Google Scholar 

  101. Hanto DW, Hopt UT, Hoffman R, Simmons R: Lymphocyte recruitment, regional blood flow, and vascular permeability at sites of allogeneic cellular interactions. J Immunol 129: 2437–2443, 1982.

    Google Scholar 

  102. Paradinas FJ, Southcott BM, O'Connell D, den Hollander F, Schuurs AH, Pulley MS, Dumonde DC: Changes induced by local injection of human lymphoid cell lymphokine into dermal metastases of breast carcinoma: a light and electron microscopical study. J Path 138: 309–323, 1982.

    Google Scholar 

  103. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983–986, 1983.

    Google Scholar 

  104. Dvorak HF, Senger DR, Dvorak AM: Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Met Rev 2: 41–73, 1983.

    Google Scholar 

  105. Dvorak HF, Dickersin GR, Dvorak AM, Manseau EJ, Pyne K: Human breast carcinoma: fibrin deposits and desmoplasia. Inflammatory cell type and distribution. Microvasculature and infarction. J Natl Cancer Inst 67: 335–345, 1981.

    Google Scholar 

  106. Paterson PY: Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed Proc 35: 2428–2434, 1976.

    Google Scholar 

  107. Blamey RW, Renney JTG, Baxter TJ, Deans BJ: The use of 125 fibrinogen in the detection of renal allograft rejection. Rat model. Transpl 16: 5–8, 1973.

    Google Scholar 

  108. Schlager SI, Dray S: Complete local tumor regression with antibody to fibrin fragment E. J Immunol 115: 976–981, 1975.

    Google Scholar 

  109. Lee FH, Fujimoto S, Sehon AH: The use of antifibrin antibodies for the destruction of tumor cells. I. Localization of antifibrin antibodies in a methylcholanthrene-induced sarcoma in guinea pigs. Cancer Immunol Immunother 5: 187–193, 1978.

    Google Scholar 

  110. Lee FH, Fujimoto S, Sehon AH: The use of antifibrin antibodies for the destruction of tumor cells. II. Indirect cell-mediated immune destruction of the guinea-pig MC-D sacroma. Cancer Immunol Immunother 5: 195–200, 1978.

    Google Scholar 

  111. Hayry P, Lindestrom BL, Virolainen M, Pasternack A, Lindfors O: Immunobiological diagnosis of rejection in dogs with renal allografts. Surg 71: 494–506, 1972.

    Google Scholar 

  112. Stewart CC: Local proliferation of mononuclear phagocytes in tumors. J Retic Soc 34: 23–27, 1983.

    Google Scholar 

  113. Gillette S, Bellanti JA: Kinetics of lymphoid cells in tumor-bearing mice. Cell Immunol 8: 311–320, 1973.

    Google Scholar 

  114. Alexander P, Hall JG: The role of immunoblasts in host resistance and immunotherapy of primary sarcomata. Adv in Cancer Res 13: 1–37, 1970.

    Google Scholar 

  115. Margolick JB, Sherwin RP: Lymphocytocidal lymphocyte trapping: dynamic characteristics of the phenomenon and the nonmacrophage identity of the lymphocytocidal trapping cell. J Reticul Soc 28: 151–165, 1980.

    Google Scholar 

  116. Margolick JB, Sherwin RP: Lymphocytocidal lymphocyte trapping: organ and species occurrence and increase in the presence of tumor metastasis. J Reticul Soc 28: 167–177, 1980.

    Google Scholar 

  117. Stutman O: Lymphocyte sequestration: its possible role in tumor immunity. Transpl Proc V: 969–973, 1973.

    Google Scholar 

  118. Gillette RW, Boone CW: Changes in the homing properties of labeled lymphoid cells caused by solid tumor growth. Cell Immunol 12: 363–369, 1974.

    Google Scholar 

  119. McCluskey RT, Benacerraf B, McCluskey JW: Studies on the specificity of the cellular infiltrate in delayed hypersensitivity reactions. J Immunol 90: 466–477, 1963.

    Google Scholar 

  120. Cohen S, McCluskey RT, Benacerraf B: Studies on the specificity of the cellular infiltrate of delayed hypersensitivity reactions. J Immunol 98: 269–273, 1967.

    Google Scholar 

  121. Pendergast RA: Cellular specificity in the homograft reaction. J Exp Med 119: 377–395, 1963.

    Google Scholar 

  122. Strom TB, Carpenter CB, Tilney NL, Suthanthiran M, Catto GRD, Lundin AP, Milford EL: Intragraft immune events causing vascularized organ graft rejection. Transpl Proc XV: 389–394, 1978.

    Google Scholar 

  123. Mule JJ, Jones FR, Hellstrom I, Hellstrom KE: Selective localization of radiolabelled immune lymphocytes into syngeneic tumors. J Immunol 123: 600–606, 1979.

    Google Scholar 

  124. Mule JJ, Hellstrom I, Hellstrom KE: Cell surface phenotypes of radiolabeled immune long-lived lymphocytes that selectively localize in syngeneic tumors. Am J Pathol 107: 142–149, 1982.

    Google Scholar 

  125. Baldwin WM, McKean WP, Clason AC, Bordes-Asnar J, Kupiec-Weglinski J, Tilney NL: Selective localization of cortical thymocytes to cardiac allografts in enhanced rats. Transpl 33: 200–202, 1982.

    Google Scholar 

  126. Nemlander A, Soots A, Von Willebrand E, Husberg B, Hayry P: Redistribution of renal allograft-responding leukocytes during rejection. II. Kinetics and specificity. J Exptl Med 156: 1087–1100, 1982.

    Google Scholar 

  127. Forbes RDC, Guttman RD: Evidence for high macrophage turnover in first-set cardiac allograft rejection: an ultrastructural tracer study in an inbred rat model. Transpl Proc XV: 1229–1231, 1983.

    Google Scholar 

  128. Evans R: Macrophages and neoplasms: new insights and their implication in tumor immunobiology. Cancer Met Rev 1: 227–239, 1982.

    Google Scholar 

  129. Eccles SA, Alexander P: Macrophage content of tumours in relation to metastatic spread and host immune reaction. Nature 250: 667–669, 1974.

    Google Scholar 

  130. Moore K, Moore M: Intratumor host cells of transplanted rat neoplasms of different immunogenicities. Br J Cancer 19: 803–813, 1977.

    Google Scholar 

  131. Liotta LA, Gattozzi C, Kleinerman J, Saidel G: Reduction of tumor cell entry into vessels by BCG-activated macrophages. Br J Cancer 36: 639–641, 1977.

    Google Scholar 

  132. Evans R, Eidlen DM: Macrophage accumulation in transplanted tumors is not dependent on host immune responsiveness or presence of tumor-associated rejection antigens. J Reticul Soc 30: 425–437, 1981.

    Google Scholar 

  133. Talmadge JE, Key M, Fidler IJ: Macrophage content of metastatic and nonmetastatic rodent neoplasms. J Immunol 23: 2245–2248, 1981.

    Google Scholar 

  134. Key ME: Macrophages in cancer metastases and their relevance to metastatic growth. Cancer Met Rev 2: 75–88, 1983.

    Google Scholar 

  135. Fidler IJ: Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines, Science 208: 1469–1471, 1980.

    Google Scholar 

  136. Sone S, Fidler IJ: Activation of rat alveolar macrophages to the tumoricidal state in the presence of progressively growing pulmonary metastases. Cancer Res 41: 2401–2406, 1980.

    Google Scholar 

  137. Hewitt HB: The choice of animal tumors for experimental studies of cancer therapy. Adv in Cancer Res 27: 149–200, 1978.

    Google Scholar 

  138. Howard JC, Butcher GW: The mechanism of graft rejection and the concept of antigenic strength. Scand J Immunol 14: 687–691, 1981.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, The Milton S. Hershey Medical Center, The Pennsylvania State University, Hershey, Pennsylvania, USA

    John W. Kreider, Gerald L. Bartlett & Bernard L. Butkiewicz

  2. Department of Microbiology, The Milton S. Hershey Medical Center, The Pennsylvania State University, Hershey, Pennsylvania, USA

    John W. Kreider, Gerald L. Bartlett & Bernard L. Butkiewicz

Authors
  1. John W. Kreider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerald L. Bartlett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernard L. Butkiewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kreider, J.W., Bartlett, G.L. & Butkiewicz, B.L. Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis. Cancer Metast Rev 3, 53–74 (1984). https://doi.org/10.1007/BF00047693

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00047693

Keywords

Search

Navigation